Skip to main content

Advertisement

Table 1 Correlation of BCL2 expression with clinic-pathologic characteristics in AML among TCGA cohort

From: BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

Patient’s parameters BCL2 expression
Low (n = 87) High (n = 86) P
Sex, male/female 49/38 43/43 0.448
Median age, years (range) 61 (22–82) 56 (18–88) 0.106
Median WBC, ×109/L (range) 17.9 (0.6–223.8) 15.25 (0.4–297.4) 0.041
Median PB blasts, % (range) 24 (0–94) 46 (0–98) 0.033
Median BM blasts, % (range) 73 (30–98) 72 (30–100) 0.893
FAB classifications    0.000
 M0 4 12 0.038
 M1 15 29 0.015
 M2 21 17 NS
 M3 5 11 NS
 M4 22 12 NS
 M5 16 2 0.001
 M6 1 1 NS
 M7 1 2 NS
 No data 2 0 NS
Cytogenetics    0.239
 Normal 44 32 NS
 t(15;17) 5 10 NS
 t(8;21) 6 1 NS
 inv.(16) 3 7 NS
  + 8 3 5 NS
 del(5) 0 1 NS
 -7/del(7) 4 4 NS
 11q23 2 1 NS
 Others 10 9 NS
 Complex 9 15 NS
 No data 1 1 NS
Gene mutation
 FLT3 (+/−) 23/64 26/60 0.616
 NPM1 (+/−) 28/59 20/66 0.235
 DNMT3A (+/−) 23/64 19/67 0.595
 IDH2 (+/−) 9/78 8/78 1.000
 IDH1 (+/−) 5/82 11/75 0.124
 TET2 (+/−) 9/78 6/80 0.590
 RUNX1 (+/−) 5/82 10/76 0.188
 TP53 (+/−) 6/81 8/78 0.590
 NRAS (+/−) 5/82 7/79 0.566
 CEBPA (+/−) 7/80 6/80 1.000
 WT1 (+/−) 2/85 8/78 0.057
 PTPN11 (+/−) 3/84 5/81 0.496
 KIT (+/−) 5/82 2/84 0.443
 U2AF1 (+/−) 4/83 3/83 1.000
 KRAS (+/−) 4/83 3/83 1.000
 SMC1A (+/−) 5/82 2/84 0.443
 SMC3 (+/−) 4/83 3/83 1.000
 PHF6 (+/−) 1/86 4/82 0.211
 STAG2 (+/−) 2/85 3/83 0.682
 RAD21 (+/−) 4/83 0/86 0.121
  1. AML acute myeloid leukemia, WBC white blood cells, PB peripheral blood, BM bone marrow, FAB French-American-British classification, NS no significant